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1. Introduction 
Over the past decade there have been significant demographic changes in the HIV epidemic. 
The overall population of people living with HIV/AIDS is aging. The effect of HAART, 
aging and resulting comorbidities, such as hypertension, and diabetes add new complexity 
to HIV and related conditions such as HIV neuropathies.  
HIV -associated polyneuropathy is still the most common neurological complication of HIV 
infection and is one of the main risk factors for development of a neuropathy worldwide. 
Many types of peripheral neuropathies are seen in HIV infection depending on the stage of 
infection. The inflammatory demyelinating neuropathies both acute (Guillain-Barré 
syndrome [GBS] and chronic (chronic inflammatory demyelinating neuropathy [CIDP] 
occur mainly at the time of seroconversion or early in the course of the disease while 
syndromes associated with opportunistic infections like CMV (i.e. polyradiculoneuropathy) 
occur in the late phase of HIV infection and are related to the loss of immune function. The 
most common neuropathy in HIV-infected patients is the sensory HIV associated 
neuropathy which includes distal symmetrical polyneuropathy (DSP) and antiretroviral 
toxic neuropathy (ATN). Those patients may experience painful symptoms such as burning 
or hyperalgesia in the feet and treatment is very often focussed on management of 
neuropathic pain. However one should be aware that the high prevalence of HIV-DSP in the 
HIV population makes the coexistence of more than one neuropathic condition likely either 
because of comorbidities or aging. These complexities have led to neuropathic syndromes 
that do not meet diagnostic criteria because of overlapping syndromes. We review the 
clinical manifestations, epidemiology, clinical diagnostics, and pathophysiology as well as 
management strategies for HIV-associated polyneuropathies. 
2. Diagnostic evaluation 
One way to classify HIV-neuropathies is according to the stage of HIV disease in which they 
occur. Therefore it is mandatory to have an actual CD4 cell count. Some types of 
neuropathies such as inflammatory demyelinating neuropathies often occur during 
seroconversion, before strong immunosuppression [1-4] while others such as progressive 
polyradiculopathies associated with CMV infection are common in late stages of AIDS. 
Over the past decade there have also been significant demographic changes in the HIV 
population, which has consequently brought attention to common so called “age related 
neuropathies” now also occurring in the HIV population. Figure 1 summarizes laboratory 
www.intechopen.com
HIV Infection in the Era of Highly Active  
Antiretroviral Treatment and Some of Its Associated Complications 
 
108 
parameters that are recommended as a baseline diagnostic in patients representing with the 
clinical symptoms of neuropathy. 
 
erythrocyte sedimentation rate or C-reactive protein, complete blood count, 
comprehensive metabolic panel (blood glucose or glucose tolerance testing (GTT), renal 
function, liver function), thyroid function tests, serum B12 (serum methylmalonic acid 
with or without homocysteine for low normal vitamin B12 levels), serum 
immunofixation electrophoresis, hepatitis B and C panel, Treponema pallidum 
screening test, immune status, HIV viral load, antinuclear antigen profile. 
In case of a co infection with hepatitis C: cryoglobulins. 
Fig. 1. Basic laboratory parameters in HIV-infected patients presenting with distal 
symmetric neuropathy. 
Cerebrospinal fluid (CSF) analysis is usually acquired when an inflammatory or an 
opportunistic/neoplastic neuropathy is suspected. You have to be aware that it may reveal 
confusing results in cases of GBS or CIDP, which occur mainly in patients with high CD4 
counts. This is because asymptomatic HIV patients may show an elevated protein and a 
mild lymphocytic pleocytosis [1, 2]. CSF analysis is however very important in patients with 
CD4 counts below 200/µl in whom there is a strong suspicion of an underlying infectious or 
malignant etiology. 
2.1 Functional and morphological assessment of nerve fibers 
Neurophysiological examination has do be done in every patient presenting with 
neuropathic symptoms in order to classify the neuropathy as either axonal or demyelinating 
and to assess a subclinical large fiber involvement in patients presenting with typical small 
fiber symptoms such as burning, aching or stubbing pain mainly localized in the feet. 
Somatosensory evoked potential may be useful if a myelopathy is suspected. 
HIV-infected patients represent very often with a pure small fiber neuropathy with burning 
feet, which may be difficult to objectify because of a paucity of clinical signs and 
unremarkable electrodiagnostic studies. Advances have been made in identifying those 
patients during the last decade. Skin biopsy from the distal leg and assessment of epidermal 
nerve fiber density (ENFD) using antibodies to protein-gene product 9.5 is nowadays a 
validated tool [5, 6]. ENFD declines with age [7], which has to be taken into account with the 
increased aging of HIV-infected individuals. Beyond skin biopsy, functional measurements 
are applicable such as quantitative sensory testing or contact heat-evoked potentials 
(CHEP`s) the later evaluating late potentials of A-delta and C fibers at the scalp following 
cutaneous stimulation. It has been shown that by using CHEP`s the sensitivity to detect 
patients with predominant small fiber involvement is higher compared to convential 
electrodiagnostic techniques [8].  
2.2 Nerve biopsy 
Nerve and muscle biopsies are only required in selected cases especially in patients 
representing with rapid progressing neuropathies. Reasons to perform a biopsy are patients 
were vasculitis, amyloidosis or storage diseases are suspected. Neuropathic pain on the 
biopsy site remains in 10 to 20 % of the patients. 
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3. Subtypes of HIV-associated neuropathies 
HIV-associated neuropathies can be classified according to clinical, neurophysiological or 
histomorphological criteria. Figure 2 summarizes the HIV-associated subtypes. 
 
HIV-associated neuropathies
HIV- associated sensory neuropathy (HIV-SN) 
- distal symmetric polyneuropathy (DSP) 
- antiretroviral toxic neuropathy (ATN) 
Inflammatory Demyelinating Polyneuropathies 
- acute inflammatory demyelininating polyneuropathy (AIDP) 
- chronic inflammatory demyelininating polyneuropathy (CIDP) 
Mononeuropathy multiplex 
Autonomic neuropathy 
Diffuse infiltrative lymphocytosis syndrome 
Neuropathies due to opportunistic infections 
Fig. 2. HIV-associated neuropathies. 
4. HIV-associated sensory neuropathy (HIV-SN) 
HIV-SN is by far the most common neurological complication in HIV infection [9, 10]. HIV-
SN summarizes 2 subtypes that are clinically undistinguishable: distal symmetric 
polyneuropathy (DSP) which occurs mainly during advanced stages of HIV infection and 
antiretroviral toxic neuropathy (ATN) as a result of neurotoxic antiretroviral treatment. 
4.1 Epidemiology 
The prevalence of HIV-SN has been found to increase further. In various cohorts, its 
prevalence reaches up to 50% [11, 12]. Early epidemiological studies conducted during the 
pre HAART-era describe an annual incidence of 36% for HIV-SN compared to 21% in the 
HAART-era [11, 13]. The increasing life expectancy of HIV-infected individuals and the high 
cumulative dosage of neurotoxic antiretroviral substances, in particular ddC, ddl and d4T, 
represent the causes for the increasing prevalence [14]. Markers of advanced HIV disease 
such as low CD4 cell count (especially a CD4 nadir below 50 cells/µl), a high HIV viral load 
(> 10.000 cop./ ml) as well as a diabetes and demographic factors such as age are associated 
with increased risk of HIV-SN [15, 16]. There seems to be evidence that the prevalence of the 
mitochondrial Haplotyp T as well as the E4 isoform for Apolipoprotein E act as an 
independent risk factor for ATN and HIV-DSP [17, 18]. Moreover it is argued that APOE 
epsilon4 may play a role in nerve regeneration [18, 19]. 
Newer analyses demonstrate that HIV-SN also occurs increasingly with protease inhibitors 
as Indinavir, Saquinavir and Ritonavir [20]. However, these patients demonstrate additional 
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factors that are combined with an increased prevalence of polyneuropathies, such as 
increased age and glycometabolic disturbances. Since protease inhibitors are often applied 
as first-line therapies, the progressing HIV infection likewise induces an increase of 
polyneuropathy, which is caused by the HIV virus itself [20]. 
4.2 Clinical manifestation 
The clinical presentation of HIV-DSP and ATN is undistinguishable and similar to other 
forms of DSP. Symptoms are usually length-dependent, symmetric, mainly sensory and 
often painful. Patients may describe burning, tightness or hyperalgesia in the feet and hands 
in a classic “stocking-and-glove” like pattern. Negative sensory symptoms such as 
numbness or hypalgesia often occur while strength is relatively preserved. Deep tendon 
reflexes are reduced at the ankles compared to the knees. Hyperactive reflexes may occur in 
cases of coexisting central nervous system disease such as myelopathy as well as HIV 
dementia. Significant motor involvement raises severe doubt about the diagnosis HIV-SN, 
although slight to moderate weakness and atrophy of the intrinsic muscles of the feet may 
be a feature of advanced HIV-SN. 
4.3 Diagnostic evaluation 
Nerve conduction studies (NCS`s) show predominantly an axonal sensory pattern with 
reduction of the sensory nerve action potential (SNAP) and mild reduction of the 
conduction velocities. As it is stated above, 20% of the patients represent exclusively with 
small fiber symptoms and therefore show unremarkable NCS`s [21]. One may consider 
conducting skin biopsy in those patients, which has been shown an objective and sensitive 
tool [6, 22]. Decreased ENFD was significantly associated with high plasma HIV viral levels 
and low CD4 counts as well as higher levels of neuropathic pain [6]. 
4.4 Pathogenesis 
Although HIV-DSP and HIV-ATN represent identically in clinical and neurophysiological 
examination they have different pathogenesis.  
4.4.1 HIV-DSP 
The pathogenesis of HIV-DSP is incompletely understood, but is likely immune mediated.  
The most characteristic pathological feature is the distal degeneration of long axons [4] 
accompanied by macrophage infiltration [4, 23] and either the absence or modest loss of 
neurons in the sensory dorsal root ganglia (DRG) [24-26]. Furthermore, there is degeneration 
within the centrally directed extension of sensory DRG neurons [26]. These findings have 
led to the hypothesis that the primary pathology could be at the level of the sensory neurons 
in the DRG, leading secondarily to a dying back process with axonal degeneration. The 
diminution and degeneration of epidermal nerve fibers as seen in skin biopsies proves this 
hypothesis [6]. People with HIV infection have also significantly reduced rates of both 
collateral and regenerative sprouting in skin biopsy experimental injury models [27]. 
The presence of HIV-infected perivascular macrophages has been shown in the DRG of 
patients with and without DSP. These studies demonstrated the presence of HIV proviral 
DNA, mRNA, p24 antigen in these cells [28-31]. Another consistent neuropathological 
abnormality in the DRG appears to be the presence of activated macrophages, which express 
MHC antigens and pro-inflammatory cytokines [4, 29, 31]. HIV-DSP correlates with the 
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degree of macrophage activation [32]. Taken together, this has led to the hypothesis that 
activated macrophages play an important role in the pathogenesis of peripheral neuropathy. 
Two possible neuropathogenetic mechanisms have been proposed; the direct effect of HIV 
or HIV proteins such as gp120 on DRGs [33-35] and the indirect neurotoxicity of products 
secreted by activated macrophages [32]. The later assumption is underlined by our 
observation that supernatants from HIV-infected macrophages induce neuritic retraction in 
DRG culture, suggesting that activated macrophages may secrete neurotoxic mediators [36]. 
4.4.2 ATN 
The increased survival time in the AIDS stage leads to a significantly higher cumulative 
dosage of antiretroviral agents. The toxicity of HAART is produced by a dysfunction in the 
mitochondria itself and mitochondrial DNA. There is evidence that the primary target in 
ATN is not the DRG itself but the axon [37]. Dalakas et al. described structural abnormalities 
in axonal mitochondria as well as mitochondria of Schwann cells in patients with ATN [38]. 
Mitochondrial DNA in subcutaneous fat was significantly reduced in patients currently 
taking Nucleoside reverse transcriptase inhibitors (NRTIs) but did however not correlate to 
the incidence of ATN [39].  
Ddl, ddC and d4T show toxic effects on the mitochondrial DNA in tissue cultures as well. 
PC12 cells exposed to ddl and ddC triggered structural modifications to the mitochondria 
and an increase in lactate production [40]. These effects are correlated with the concentration 
of these substances. The initial changes to the mitochondrial ultrastructure occurred after 
only a few days. The toxic potential for the induction of these changes can be arranged in 
the following sequence: ddC > d4T > ddI [41]. The higher toxicity of ddl, ddC and d4T in 
comparison to other antiretroviral agents results from the diverse inhibition of 
mitochondrial enzymes as γ-polymerase. However there seems to be γ-polymerase 
independent pathways of mitochondrial damage [42]. 
4.5 Therapy 
4.5.1 Causal 
There is no approved causal treatment for HIV-associated DSP. There is however some 
evidence that HAART may improve symptoms [43]. Early epidemiological studies 
conducted during the pre HAART-era describe an annual incidence of 36% for HIV-SN 
compared to 21% in the HAART-era [11, 13] which also indicate some positive influence of 
HAART. 
If the patient is taking neurotoxic medications they should be stopped or changed if it is 
possible. One has to check for potentially neurotoxic co medications that are often used for 
HIV-related conditions such as chloramphenicol, dapsone, ethambutol, etopside, isoniazid, 
metronidazole, pyridoxine, thalidomide, and vincristine [44].  
Clinical trials of potentially neuroregenerative therapies such as nerve growth factor [45], 
prosaptide [46] and timcodar [47], agents that were neurotrophic in vitro and in animal 
models have failed. 
4.5.2 Pain management 
Neuropathic pain can be quite disabling for the patients and treatment is often challenging 
because of concomitant diseases and relevant interactions of neuropsychopharmacologically 
active drugs with HAART. 
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Recommendations are based on studies performed specifically in HIV-SN, but also 
extrapolated from studies performed in various conditions such as painful diabetic 
neuropathy as well as postherpetic neuralgia. Six main classes of agents are used: 
anticonvulsants (calcium- and sodium–dependent), antidepressants, opioids, topical 
treatments, nonspecific analgesics and alternatives therapies. 
A recently published review and meta-analysis describes randomized controlled trials 
(RCT`s) evidence of analgesic efficacy superior to placebo in the context of HIV-SN pain 
only for smoked cannabis, recombinant nerve growth factor (rhNGF) and high dose (8%) 
topical capsaicin [48]. Several other agents have been examined in RCTs and found to be not 
effective such as acetyl-L carnitine (1g/day), amitriptyline (100mg/day), topical capsaicin 
0.075%, gabapentin (2.4g/day), mexilitine (600mg/day), peptide –T (6mg/day), pregabalin 
(600mg/day), lamotrigine (600mg/day) and prosaptide (16mg/day) [48, (Simpson, Schifitto 
et al. 2010)]. Prospective RCT´s show however an effectiveness for gabapentin (up to 3.6g/d) 
[49] in HIV-DSP as well as lamotrigene in ATN [50].  
Gabapentin and pregabalin do not induce the cytochrome P-450 system and are therefore 
preferred agents. Older antiepileptics such as carbamazepine should be avoided as a result 
of multiple and pronounced interactions [51, 52]. There are also promising data for 
duloxetine in reducing pain. However RCT´s were performed in patients with painful 
diabetic neuropathy [53, 54]. Duloxetine is characterized by nearly no interactions with 
HAART and is therefore an interesting alternative. Even though the older, tricyclic 
antidepressants have not be convincing in one RCT [55] they are very well suited for 
neuropathic pain therapy in our clinical experience. However it has to be taken into 
consideration that amitriptyline levels are increased by protease inhibitors, which may 
provoke side effects.  
5. Inflammatory demyelinating polyneuropathies 
Acute inflammatory demyelinating polyneuropathy (AIDP or Guillain-Barré- syndrome 
[GBS]) or chronic inflammatory demyelinating polyneuropathy (CIDP) may occur early in 
the course of HIV disease as a part of the acute antiretroviral syndrome or in a stage where 
the CD4 cell count is above 250/µl [1, 2, 56].  
5.1 HIV-AIDP 
In our clinical experience HIV-AIDP is a rare disease. It has not been seen in prospective 
studies of HIV infection [57]. A Zimbabvian study of 32 consecutive patients with AIDP 
found that 55% suffered from HIV, while the seroprevalence of HIV infection during the 
time the study took place was estimated at 4.3%, clearly indicating a relationship [2]. 
Cornblath et al. [1] described three patients with HIV-AIDP early in HIV infection, prior to 
AIDS. Subsequent reports also indicated that HIV-AIDP occurs at time of seroconversion 
[58, 59]. HIV-AIDP is considered to precede AIDS but has been described in HIV-infected 
patients with a CD4 cell count below 200 but above 50/µl [56, 60]. The last remark is 
important as one has always to consider an opportunistic polyradiculitis in patients 
presenting with symptoms consistent with HIV-AIDP but CD4 cells below 50/µl. Those 
patients should be treated presumptively for CMV infection until the CMV polymerase 
chain reaction (PCR) in CSF is negative. 
The clinical manifestation is similar to those seen in HIV-negative patients with AIDP. First 
symptoms are distal pain, numbness, paraesthesia, or weakness in the limbs rapidly 
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progressing into a relatively symmetric weakness of the limbs with or without involvement 
of respiratory muscles or cranial nerve-innervated muscles [61]. Diagnostic evaluation for 
HIV-AIDP typically includes cerebrospinal fluid analysis (CSF) which might be misleading 
on the first glance because about 50% of the patients show mild lymphocytic pleocytosis (up 
to 50/µl) and elevated protein [62]. CSF analysis is especially important in patients with 
CD4 cell counts far below 200/µl in whom the suspicion of an underlying opportunistic or 
malignant etiology is high. 
Treatment recommendations are derived from experiences in HIV-negative patients and 
include either plasmapheresis (5-7 times) or intravenous immunoglobulin (IVIg) (2g/kg/body 
weight) [61]. The prognosis is in general good with an almost complete remission in more than 
50% of the patients [10, 56]. It seems that the relapse rate of HIV-AIDP or the development of a 
secondary chronic disease (CIDP) seems to occur more often [56]. 
5.2 HIV-CIDP 
HIV-CIDP is a rare disease but in our clinical experience more common than HIV- AIDP. 
Patients may present with similar clinical features like their HIV-negative counterparts but 
one may observe overlaps with other subtypes of HIV-associated neuropathies such as HIV-
DSP or ATN which can make the diagnose challenging. 
Typical clinical features include an acute or subacute onset of symptoms progressing for at 
least 8 weeks, a relapsing/remitting course, sometimes an asymmetrical pattern, a lack of 
length-dependent sensory deficits, or the presence of marked large fiber sensory deficits 
[63]. Sensory symptoms usually consist of numbness and tingling, but painful paresthesias 
may be present. Many patients have impaired balance due to proprioceptive deficits [63]. 
Weakness usually involves both proximal and distal muscles, but can be purely distal. 
Patients may reveal concomitant cranial nerve deficits [63]. As stated previously, there 
seems to be a higher risk for HIV-infected patients to progress from AIDP into CIDP. Those 
patients warrant careful consideration and follow-up as they are at risk for relapses that will 
require sustained treatment.  
CSF analysis is usually performed, but as already mentioned shows mild lymphocytic 
pleocytosis (up to 50/µl) and elevated protein in up to 50% of the patients [62]. Diagnostic 
evaluation includes NCS´s showing features of demyelination such as slowing of 
conduction velocity, prolonged distal latencies, and F-waves as well as conduction blocks 
and temporal dispersion [64]. Electromyography may reveal mild pathological spontaneous 
activity [1, 64]. A magnetic resonance image (MRI) with and without gadolinium of the 
corresponding spinal segments is not obligatory but is strongly recommended in patients 
with a CD4 cell count below 200/µl to exclude infiltrative processes in the nerve roots. A 
sural nerve biopsy is rarely necessary but may be helpful in patients representing with 
atypical clinical signs. 
There are no RCT´s in HIV-CIDP investigating treatment options. Therefore we follow the 
treatment recommendation for the non HIV-CIDP counterparts, where RCT´s have 
demonstrated the efficacy of corticosteroids [65], plasma exchange [66, 67], and IVIg [68, 69]. 
In our view IVIgs (loading dose 2g/kg/body weight) are the best choice to start with. 
Corticosteroids (1mg/kg/body weight for 2-4 weeks and than tapering down or switching 
into an alternate-day therapy) might be another option, but one has to consider potential 
side effects such as immunosuppression, increased risk of osteonecrosis of the femoral head, 
osteoporosis and metabolic derangement. They are only a choice if the patient receives a 
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stable HAART. Plasma exchange is typically used if patients are severely weak or if they 
relapse on prednisone or IVIg [63]. Many patients require a sustained therapy but there is no 
general paradigm.  
6. Mononeuropathy and mononeuropathy multiplex 
We do see mononeuropathies with HIV-infection and they are often described in the 
literature [10, 22, 70]. There are however no data about the incidence. They are occurring 
mainly as focal cranial neuropathies such as unilateral or bilateral facial palsy [71-73]. They 
are described in the context of seroconversion [71] but can occur also during later stages of 
HIV disease. If a patient is relevantly immunosuppressed one has to consider varicella 
zoster virus (VZV) as well as neoplastic etiologies [72]. 
It is unclear whether HIV-associated mononeuropathies should prompt one to start 
HAART. Since we are lacking data to answer that question it cannot be recommended yet. 
The prognosis is in general good. 
Mononeuropathy multiplex (MM) is a rare disease in HIV. Patients represent often with 
rapidly progressive multifocal deficits and pain. The underlying etiology differs according 
to the stage of HIV-disease. Mononeuropathy multiplex in patients with a high CD4 count is 
probably immune-mediated. In contrast in patients with advanced AIDS it represents 
mainly an opportunistic infection like CMV-MM and shows a more severe course compared 
to the immune-mediate variant. Because of the high rate of co-infection with hepatitis C and 
secondary cryoglobulinemia it should be always considered a potential differential 
diagnosis. 
Nerve conduction studies reveal axonal damage [74] and electromyography relevant 
pathological spontaneous activity in the clinically involved muscles. A CSF analysis is 
obligatory in patients with AIDS to search for the underlying pathology (PCR for CMV). 
Sural (or an alternative clinically involved nerve) biopsy if often required to show 
inflammatory CD8 infiltrates. 
If a CMV associated mononeuropathy multiplex is suspected you may choose to treat 
empirically with ganciclovir and attempt HAART. The prognosis is however poor. 
In patients with a high CD4 count and a suspected immune-mediated form patients may 
benefit from IVIg (2g/kg/body weight) or corticosteroids (100mg/d for 2 weeks, than 
tapering down). There are however no evidence based guidelines. 
7. Autonomic neuropathy 
It is not clear whether an autonomic HIV-associated neuropathy should be described as an 
isolated entity because according to our knowledge it is not known, that patients present 
with purely autonomic symptoms [10]. Autonomic symptoms however are often in other 
HIV-neuropathies, for instance HIV-SN. Studies investigating autonomic functions in HIV-
infected patients describe different in part contrary results [75-79], which urges the need for 
larger RCT´s.  
8. Diffuse infiltrative lymphocytosis syndrome (DILS) 
DILS is a very rare systemic disease involving several organs including the peripheral 
nervous system. To our knowledge it occurs exclusively in HIV-infected patients [80, 81] 
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during the middle or advanced stages of HIV disease while the CD4 cells are below 500/µl. 
The most common manifestations are bilateral parotid enlargement, pulmonary 
insufficiency, and lymphadenopathy [81]. Neurological manifestations of DILS include 
peripheral neuropathy, which can be the presenting symptom [82]. It has been described as 
a painful, symmetric neuropathy with acute or subacute onset. Other neurological 
manifestations are facial nerve palsy (uni- or bilateral) as well as myositis [83]. Recently a 
lumbosacral radiculoplexus neuropathy has been described as a clinical presentation of 
DILS [84]. 
The typical syndrome includes CD8-lymphomatosis (>1200/µl) and secondary infiltration of 
the visceral organ and peripheral nerves [81, 82, 85-87]. Sural nerve biopsy reveals epi- and 
endoneural infiltration by CD8 cells and vascular mural necrosis [82, 85]. Increased 
expression of HIV p24 has been demonstrated in macrophages infiltrating the nerves [80, 82, 
88]. 
DILS is a rare disease so there are no RCT´s for treatment regimens. It is described, that 
patients show improvement with corticosteroids and zidovudine [82]. It is therefore 
recommends to initiate or continue HAART and start with corticosteroids (1 mg/kg body 
weight for 4 weeks than tapering slowly down to 10-20 mg) [70]. 
9. Radiculopathies 
Progressive polyradiculopathy is seen in patients with advanced AIDS [89]. They are mainly 
CMV-associated but can be also caused by Treponema pallidum, VZV, EBV, HSV, 
mycobacterium tuberculosis or cryptococcus neoformans [62, 90-92]. Patients present with a 
rapidly evolving cauda equina syndrome, including weakness and numbness in the lower 
extremities and sphincter dysfunction [90].  
Mandatory diagnostic evaluation includes an MRI of the lumbosakral spine, which may 
show meningeal enhancement [93] as well as CSF analysis. A spinal tap is essential to 
confirm the underlying opportunistic infection in the CSF (PCR) as well as malignancy 
(cytology). CSF can be surprisingly unremarkable which would still not exclude the 
diagnosis [94] because of the severe immunosuppression. Nerve conduction studies reveal 
severe axonal damage in the lower extremities combined with extensive pathological 
spontaneous activity in the electromyography. If a CMV infection is suspected it would 
speed up the diagnose to search for evidence of CMV infection in other organs (retinitis, 
pneumonitis, hepatitis) [10, 22]. 
Treatment follows the underlying etiology [95]. In cases of CMV - polyradikulitis ganciclovir 
is effective or alternative foscarnet, and cidofovir [89, 96, 97]. 
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